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Research Article
Histone deacetylase inhibitors prevent
persistent hypersensitivity in an orofacial
neuropathic pain model
Robert J Danaher1, Liping Zhang1,2, Connor J Donley2,
Nashwin A Laungani1, S Elise Hui3, Craig S Miller1, and
Karin N Westlund2,3
Abstract
Chronic orofacial pain is a significant health problem requiring identification of regulating processes. Involvement of epigenetic
modifications that is reported for hindlimb neuropathic pain experimental models, however, is less well studied in cranial nerve
pain models. Three independent observations reported here are the (1) epigenetic profile in mouse trigeminal ganglia (TG)
after trigeminal inflammatory compression (TIC) nerve injury mouse model determined by gene expression microarray, (2)
H3K9 acetylation pattern in TG by immunohistochemistry, and (3) efficacy of histone deacetylase (HDAC) inhibitors to
attenuate development of hypersensitivity. After TIC injury, ipsilateral whisker pad mechanical sensitization develops by day
3 and persists well beyond day 21 in contrast to sham surgery. Global acetylation of H3K9 decreases at day 21 in ipsilateral TG .
Thirty-four genes are significantly (p< 0.05) overexpressed in the ipsilateral TG by at least two-fold at either 3 or 21 days post-
trigeminal inflammatory compression injury. The three genes most overexpressed three days post-trigeminal inflammatory
compression nerve injury are nerve regeneration-associated gene ATF3, up 6.8-fold, and two of its regeneration-associated
gene effector genes, Sprr1a and Gal, up 174- and 25-fold, respectively. Although transcription levels of 25 of 32 genes
significantly overexpressed three days post-trigeminal inflammatory compression return to constitutive levels by day 21,
these three regeneration-associated genes remain significantly overexpressed at the later time point. On day 21, when tissues
are healed, other differentially expressed genes include 39 of the top 50 upregulated and downregulated genes. Remarkably,
preemptive manipulation of gene expression with two HDAC inhibitors (HDACi’s), suberanilohydroxamic acid (SAHA) and
MS-275, reduces the magnitude and duration of whisker pad mechanical hypersensitivity and prevents the development of a
persistent pain state. These findings suggest that trigeminal nerve injury leads to epigenetic modifications favoring overexpres-
sion of genes involved in nerve regeneration and that maintaining transcriptional homeostasis with epigenetic modifying drugs
could help prevent the development of persistent pain.
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ic regulation
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Introduction
Histone deacetylase inhibitors (HDACi) show promise
as treatment for neuropathic pain. The efficacy of epige-
netic modifying drugs for treatment of models of hind-
limb neuropathic pain has been well established,1 but
studies currently involving the role of epigenetics in oro-
facial pain and thus the efficacy of epigenetic modifying
drugs associated with orofacial pain has lagged behind
1Department of Oral Health Practice, College of Dentistry, University of
Kentucky, Lexington, KY, USA
2Department of Physiology, College of Medicine, University of Kentucky,
Lexington, KY, USA
3Department of Anesthesiology & Critical Care Medicine, University of
New Mexico Health Science Center, Albuquerque, NM, USA
Robert J Danaher, Liping Zhang, Connor J Donley, and Nashwin A Laungani
contributed equally to this work.
Corresponding Author:
Karin N Westlund, New Mexico VA Health Care System, 1501 San Pedro
Drive SE, Albuquerque, NM 87108, USA.
Email: khigh@salud.unm.edu
Molecular Pain
Volume 14: 1–20
! The Author(s) 2018
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/1744806918796763
journals.sagepub.com/home/mpx
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-
NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and dis-
tribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.
sagepub.com/en-us/nam/open-access-at-sage).
this rapidly advancing field. There are four classes of
HDACs: zinc-dependent HDACs I (HDAC 1–3 and
8); IIa (HDAC 4, 5, 7 and 9); IIb (HDAC 6 and 10);
and IV (HDAC 11); and biochemically unique class III,
a family of NADþ-dependent proteins known as sirtuins
(SIRT 1–7) involved particularly in mitochondrial bio-
genesis. The highest expression of HDAC 1 (class I) has
been shown in injured dorsal root ganglia (DRG) fol-
lowing spinal nerve ligation.2 Evidence that epigenetic
changes are involved in the development of neuropathic
pain has been shown since class I HDACi’s (HDACi)
treatments with suberanilohydroxamic acid (SAHA) and
MS-275 produce analgesia in sciatic nerve injury
models.3–5 Both experimental and clinical studies have
demonstrated class II HDACi’s (trichostatin A, givino-
stat (ITF 2357)) have therapeutic potential for inflam-
matory conditions.6–8 Four HDACi’s are already Food
and Drug Administration (FDA) approved for treat-
ment of some forms of cancer.9 A potential benefit of
HDACi’s for neurodegenerative diseases, such as
Alzheimer’s and Huntington’s, has also been
described.10,11 These drugs work by modifying DNA
or DNA-associated proteins such as histones such that
gene expression can be manipulated, possibly restoring
homeostatic expression levels. Whether HDACi’s pro-
duce analgesia or influence the transition from acute to
persistent pain in models of orofacial neuropathic pain is
not yet well studied. Thus, we examined the epigenetic
changes in TG due to trigeminal nerve injury as a first
step and determined whether HDACi’s would reduce the
pain-related behaviors induced by the trigeminal inflam-
matory compression (TIC) nerve injury model in mice.
Two class I HDACi’s, SAHA and MS-275, were
tested in this study.12 SAHA, also named Vorinostat,
(the trade name is Zolinza), is a class I and II HDACi
that was the first HDACi approved by the U.S. FDA for
the treatment of cutaneous T-cell lymphoma.13 MS-275,
Entinostat, also known as SNDX-275, is a benzamide
class I inhibitor of HDAC 1 (IC50¼ 300 nM) and
HDAC 3 (IC50¼ 8mM) that is undergoing clinical
trials for the treatment of various cancers.
Materials and methods
Animals
Three experiments were performed with male BALB/C
mice with and without TIC nerve injury following
behavioral testing:
1. Microarray (four groups of n¼ 6 each, total of 24
mice, only three ipsilateral TGs per group were used
for each microarray). The four groups were: 3-day
naı̈ve, 3-day TIC, 21-day naı̈ve, and 21-day TIC;
2. Immunohistochemistry (four groups of n¼ 3 each,
total of 12 mice). The four groups were: 3-day
naı̈ve, 3-day TIC, 21-day naı̈ve, and 21-day TIC.
Measurement of ipsilateral TG neuron diame-
ters (n¼ 3);
3. HDACi’s treatment (three groups of n¼ 5 each, total
of 15 mice). The three groups were: TICþVehicle,
TICþ SAHA, TICþMS275.
Mice received from Envigo-Harlan (Indianapolis, IN)
weighed between 20 and 22 g during the week of accli-
mitization. BALB/c mice with hypersensitivity are con-
sistently easier to handle in repeated pain-related
behavioral testing paradigms extending over numerous
weeks. Mice were kept in ventilated animal housing with
constant temperature (23  2C) on a reversed 10/14
h dark/light cycle. Food and water were provided ad
libitum. Experiments were carried out in accordance
with the guidelines established by National Institute of
Health (NIH) and the International Association for the
Study of Pain regarding the care and use of animals for
all experimental procedures. Protocols were approved by
the Institutional Animal Care and Use Committee at the
University of Kentucky.
Induction of TIC nerve injury
All surgeries were completed in a sterile environment
under a surgical microscope in mice anesthetized with
isoflurane (2–5%) as validated previously.14,15 The top
of the head was shaved and the mice secured in a stereo-
tactic frame. In order to prevent the eyes from drying
out during the operation, Artificial Tears Ointment
(Rugby Laboratories, Inc. Duluth, GA) was applied to
both eyes. A 15-mm skin incision was made in an ante-
rior to posterior direction at the midline of the head. The
conjunctiva of the orbit was opened along the top inner
corner of the left eye bony orbit (eye socket) with the tip
of a surgical scalpel. Cotton balls were used to minimize
bleeding within the orbital cavity and as tools for blunt
isolation of the infraorbital nerve lying in the infraorbi-
tal bony fissure. The infraorbital nerve was freed from
the bone in the orbital cavity in order to insert a 2 mm
length of 6–0 chromic gut suture between the infraorbital
nerve and the maxillary bone, positioned as close to the
anterior maxillary nerve branch as possible. Skin inci-
sions were closed with 5–0 nylon non-absorbable mono-
filament suture. Mice were given a three-day recovery
period prior to further behavioral testing.
Exon microarray and gene expression
profiling analysis
Gene expression profiling was performed on TGs from
mice with/without TIC nerve injury during the acute
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phase (3 days) and persistent (21 days) post-injury time
points for comparisons to their corresponding naı̈ve con-
trol groups (n¼ 24). The TGs were freshly dissected,
transferred to RNAlaterVR , a RNA stabilization solution
(Life Technologies, Grand Island, NY), and stored at
80C. Total RNA from ipsilateral TGs was isolated
using the RNeasy Mini Kit (Qiagen, Valencia, CA).
Each replicate was derived from a single ipsilateral TG
from n¼ 3 mice per group/per time point and run in
duplicate. RNA expression levels were determined with
the Mouse Gene 2.0 Array (Affymetrix, Santa Clara,
CA, USA) at MicroArray Core Facility under the direc-
tion of Dr Kuey-Chu Chen in the University of
Kentucky. The Mouse Gene 2.0 Array contained
41,345 transcript cluster sets.
The gene ontology (GO) for each transcript was
obtained using the NIH gene database (https://www.
ncbi.nlm.nih.gov/gene). We used the GO annotation
analysis corresponding to the Mus musculus (house
mouse) description since this most closely correlates to
the BALB/C mice used in the research protocol. Process,
function, and pathway enrichment analysis was per-
formed using The Database for Annotation,
Visualization and Integrated Discovery (DAVID) v6.
8 (National Institute of Allergy and Infectious
(NIAID)/NIH).16,17 The Kyoto Encyclopedia of Genes
and Genomes (KEGG) was used in differentiating genes
in the pathway analysis. Biological processes, molecular
functions, and pathways influenced by TIC injury were
identified. Gene expression profiling with Affymetrix
Gene Chip Analysis Suite 5.0 software was performed.
Data were analyzed at the transcript cluster level; sta-
tistical analysis of the transcript cluster-level data was
done via paired t-tests. Correction for multiple testing
was done using a stepwise procedure at a false discovery
rate of 5%.18–20
Quantitative real-time PCR (qPCR)
RNA was reverse transcribed and quantified by quanti-
tative real-time PCR.21 Sprr1a, Gal, Atf3, and GAPDH
TaqMan gene expression assays were purchased from
Life Technologies Corporation (Carlsbad, CA). Real-
time PCR was performed on an ABI Prism 7700
Sequence Detection system (PE Applied Biosystems,
Foster City, CA, USA) in a 20 ml reaction volume con-
sisting of final concentrations of 1X TaqMan Universal
PCR master mix (PE Applied Biosystems) and 1
respective gene expression assays using default condi-
tions. Relative mRNA levels were calculated by 2–(CT
testCT GAPDH)  100% using GAPDH as the reference
gene.22
Immunofluorescent staining
The TGs were dissected from 4% paraformaldehyde per-
fused mice, cryoprotected in 30% sucrose prior to freez-
ing, and cryosectioned (10 mm). Serial sets were collected
for immunostaining with 100 mm between sections to
allow non-overlapping cell counts. Each serial set with
five to seven sections was mounted onto SuperfrostVR
Plus microscope slides (VWR, Radnor, PA) and stored
at 80C. On the day of immunostaining, the sections
were blocked in 3% normal goat serum (NGS) and then
incubated overnight at room temperature with the pri-
mary antibody mixture in 3% NGS: rabbit polyclonal
anti-acetyl histone H3K9 antibody (1:300, Epigentek
Group) and mouse monoclonal anti-neuronal nuclei/
plasma (NeuN) (1:300, Millipore Corporation). To
study the H3K9 expression in non-neuronal cells, dual
staining was done to localize immunoreactivity for glu-
tamine synthetase (Gl Syn, E-4 antibody, 1:300; Santa
Cruz Biotechnology, INC) to identify the satellite glial
cells. Sections were washed the next day with 0.1 M PBS
(pH 7.4) and incubated with secondary antibodies for 1
hour: goat anti-mouse IgG Alexa Fluor 594 and goat
anti-rabbit IgG Alexa Fluor 488 (1:1000; Invitrogen,
Grand Island, NY). After 3 5 min 0.1 M PBS (pH
7.4) washes, the slides were coverslipped with anti-fade
mounting media (Vector Laboratories, Burlingame,
CA). Images of TG sections were collected with
MetaVue Program (Molecular Devices, Sunnyvale,
CA) using a Nikon E100 microscope (Nikon
Instruments, Inc., Melville, NY).
Image analysis
Multiple images were captured from 5 to 7 tissue sec-
tions with 100 mm interspacing to span the entire trigem-
inal ganglia (TG) of each animal for analysis with the
Metamorph off-line program. Images from each of the
TG sections were stitched together with computer assis-
tance allowing identification of V1, V2, or V3 TGs. TG
neurons were measured with the Metamorph off-line
program and classified by their diameters. Anti-NeuN
antibody staining was used to visualize the TG neurons
and allowed counting of 3,000–6,000 neurons for the V2
TG by investigators blinded to experimental group des-
ignation for comparisons among experimental groups.
The number of neurons labeled with H3K9ac was
counted to determine the percentage of total neurons
double labeled with NeuN and H3K9ac for comparisons
between animals with/without TIC injury.
Detection of whisker pad mechanical hypersensitivity
Behavioral threshold measurements on the whisker pads
were taken pre-surgery as baseline and at post-surgery
days 3, 7, 14, 21, and 28. The mice were acclimated to the
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testing room 30 min prior to testing. Mice were previ-
ously habituated to investigators and the von Frey fila-
ments several times prior to data collection. Mechanical
thresholds of the whisker pad-infraorbital nerve recep-
tive field were determined using the modified up-down
method23 as we described previously for the TIC
model.14,15 Eight graded von Frey fiber filaments
(0.008 g (1.65); 0.02 g (2.36); 0.07 g (2.83); 0.16 g
(3.22); 0.4 g (3.61); 1.0 g (4.08); 2.0 g (4.31); 6.0 g
(4.74); Stoelting, Wood Dale, IL) were used to determine
mechanical sensitivity beginning with the 3.22 filament.
During testing, mice were gently restrained in soft cotton
gloves with their head exposed for application of von
Frey filament to the whisker pads on both sides. Each
filament was applied up to five times to obtain three
positive or negative responses with at least 5 s intervals
between stimulations. Head withdrawal from the fila-
ment or a paw swipe was considered a positive response.
Data were analyzed with a curve-fitting algorithm that
allowed for calculation of the 50% mechanical with-
drawal threshold (in gram force). A decreased mechan-
ical threshold is an index of mechanical hypersensitivity
or allodynia.
Drug treatment
The pan-HDAC inhibitor SAHA (50 mg/kg) and
HDAC1-selective inhibitor MS-275 (3 mg/kg) (Cayman
Chemical Company, Ann Arbor, MI) were dissolved in
30% dimethyl sulfoxide (DMSO) in normal saline and
administered over a prolonged 12-day drug treatment
scheme spanning the day of surgery.5 Drugs and vehicle
controls (30% DMSO in saline) were given subcutane-
ously (s.c.) for five consecutive days prior to and contin-
ued for seven consecutive days following TIC injury.
Behavioral testing was done every other day during
drug treatments for comparisons to pre-
treatment baselines.
Statistical analysis
Whisker pad mechanical thresholds were averaged for
naı̈ve or TIC-injured mice receiving SAHA, MS-275,
or vehicle. The behavioral data were expressed as
meanSE using two-way analysis of variance
(ANOVA) with post-hoc testing with Tukey’s multiple
comparisons over time. The percentages of H3K9ac-
positive neurons were averaged for naı̈ve and TIC
injury animals and compared using Student’s t-tests. A
p value of  0.05 was considered significant. Statistical
analysis of the transcript cluster-level data comparisons
was done via paired t-tests.
Results
Mechanical hypersensitivity develops on the ipsilateral
whisker pad after TIC injury
Mechanical hypersensitivity developed on the ipsilateral
whisker pads by day 3 post-TIC injury in contrast to
naı̈ve controls or the contralateral whisker pads
(Figure 1). Six mice were euthanized for gene expression
profiling for each group on days 3 and 21. Compared to
the average ipsilateral baseline mechanical threshold of
all mice (3.02 0.36 g), mechanical threshold decreased
on the ipsilateral whisker pad to an average of 0.02
 0.006 g by day 3 after TIC injury. The mechanical
threshold remained at a low level through day 21 (0.11
 0.06 g), indicating success in producing stable mechan-
ical hypersensitivity on the side ipsilateral to the nerve
injury (Figure 1(a)). Compared with their own baseline
and with the naı̈ve control group, mechanical hypersen-
sitivity of the ipsilateral whisker pad of TIC-injured mice
was statistically significant at all the time points tested.
Figure 1. Trigeminal nerve injury (TIC) causes persistent
mechanical hypersensitivity of the ipsilateral whisker pad. The
average 50% mechanical threshold value (grams force) was deter-
mined with von Frey fiber stimulation of the ipsilateral (a) and
contralateral (b) whisker pads of mice with/without TIC injury
(n¼ 6 per group). The averaged thresholds for naı̈ve () and TIC
nerve injury () mice are shown. The ipsilateral and contralateral
averages of mechanical threshold values for naı̈ve mice are similar
as expected. The contralateral mechanical threshold values of TIC
injury mice were similar to naı̈ve controls and did not change from
their baseline over time. ***p< 0.001, two-way ANOVA, Tukey’s
multiple comparisons test, n¼ 6 per group.
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The averaged mechanical threshold for the contralateral
whisker pad (2.74 0.45 g) after TIC injury was similar
to the naive controls (2.378 0.49 g) (Figure 1(b)).
Genes differentially expressed in TG following
TIC injury
Transcriptional expression changes caused by TIC injury
at the genome-wide level were analyzed by gene expression
profiling of ipsilateral TGs at day 3 and 21 post-injury.
Total RNA was isolated and processed for Mouse Gene
2.0 Array analysis. We identified 27,985 transcript cluster
sets associated with gene assignments according to the
supplier and/or DAVID (Database for Annotation,
Visualization and Integrated Discovery NIAID/NIH, see
https://david.ncifcrf.gov).15,16 Of these, signal intensities of
367 were increased >50% and two were decreased >50%
in mice on day 3 post-TIC injury compared to n€aives. On
day 21 post-TIC injury, 56 were increased >50% and 66
were decreased >50% (data available upon request).
Top 50 differentially expressed genes. The 50 genes most up-
and downregulated by at least 50% are presented in
Tables 1 and 2, for the days examined. Of note, the
small proline-rich repeat protein 1A (Sprr1a), an axon
regeneration-associated gene (RAG), was
induced> 174-fold three days after TIC injury and
remained upregulated> 15-fold three weeks after TIC
injury. In addition, two other RAGs, Gal and Atf3,
were highly upregulated 25- and 7.8-fold on day 3,
respectively, and remained upregulated 2.4- and 2.7-
fold three weeks post-TIC injury.
Differentially expressed genes after TIC injury unique to days 3
and 21. Most striking was the large number of genes on
day 21 of the 50 most up- and downregulated that were
not expressed on day 3. The differentially expressed genes
at day 21 not in common with day 3 are presented in
BOLD font in Table 2. This included 39 upregulated
genes and 34 downregulated genes at 21 days. Genes
uniquely expressed on day 3, shown highlighted in
BOLD font in Table 1, included 24 upregulated genes
and 1 downregulated gene. It is important to note that
due to the experimental design of this study, it is not
possible to distinguish tissue injury-mediated gene expres-
sion changes at day 3 from expression mediated by nerve
injury. This may account for some of the differences
noted between days 3 and 21 gene expression profiles.
Common gene ontologies and transcript cluster sets. Of the
50 genes most up- and downregulated, there were
27 transcripts in common between days 3 and 21.
Among these 27 transcripts, there were 17 common
gene ontologies presented in Table 3 arranged with the
most upregulated transcript first and ending with the
most downregulated transcript for day 3 post-TIC.
Using the NIH “Process” ontology, common ontologies
included peptide cross-linking, inflammatory response,
chemokine-mediated signaling pathway, immune
system process, innate immune response, defense
response to bacterium, neuropeptide signaling pathway,
G-protein-coupled receptor signaling pathway, signal
transduction, ion transport, positive regulation of tran-
scription by RNA polymerase II, positive regulation of
gene expression, positive regulation of cell proliferation,
biological process, proteolysis, lipid catabolic process,
and lipid metabolic process.
Overall, signal intensities of 1902 and 1392 transcript
cluster sets were significantly different from naı̈ve con-
trols at days 3 and 21 post-TIC injury (p< 0.05), respec-
tively. These transcript cluster sets, regardless of
magnitude or direction, were evaluated in DAVID to
identify enrichments of genes associated with particular
KEGG pathways, biological processes, and molecular
functions at the examined time points. Differentially reg-
ulated genes were significantly enriched for 42 KEGG
pathways at days 3 and 21 post-TIC injury (p < 0.05,
data available). Genes associated with the top 10
enriched KEGG pathways at day 3 and the only
KEGG pathway at day 21 are presented in Table 4.
Pathways of particular interest include (1) neuroactive
ligand–receptor interaction, (2) Rap1 signaling pathway,
(3) glutamatergic synapse, and (4) long-term potentia-
tion. There was significant enrichment of genes associat-
ed with 54 biological processes and 29 molecular
functions on day 3 post-TIC injury. Thirty biological
processes and 12 molecular functions were identified
from day 21 post-TIC TG (p< 0.05).
The top 10 biological processes and molecular func-
tions are presented in Table 5. Of particular interest on
day 3 are the signal transduction, activation of MAPKK
activity, cell migration, cellular response to interferon-
alpha biological processes, voltage-gated ion channel
activity, signal transducer activity, GTP binding, histone
methyltransferase activity (H3-K9 specific), transcrip-
tion factor activity, and sequence-specific DNA binding
molecular functions. The expression changes for day 3
were not unexpected based on previous studies. At day
21, insulin signaling pathway and resistance expression
clusters were upregulated in the TG.
Global acetylation of H3K9 in the TG after TIC injury
Acetylation of H3K9 was decreased in the TG 21 days after TIC
injury. To explore the epigenetic involvement of this TIC
nerve injury model of trigeminal neuropathic pain,
changes in global expression of H3K9 acetylation
(H3K9ac) protein were examined for the V2 TG from
mice at 3 and 21 days post-injury. H3K9ac immunore-
activity appears in the nuclei of neurons (Figure 2(a) to
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Table 1. Genes differentially regulated >50% three days post-TIC injury.
Transcript ID Gene assignment Gene symbol TIC/naı̈ve ratio p Values q Values
Upregulated
17407412 Small proline-rich protein 1A Sprr1a 174.86 4.81E-06 3.23E-04
17360942 Galanin Gal 25.96 1.52E-05 5.07E-04
17231033 Activating transcription factor 3 Atf3 7.84 6.45E-06 3.23E-04
17244601 Neurotensin Nts 7.32 2.56E-04 3.20E-03
17485098 Mucin 5, subtype B, tracheobronchial Muc5b 6.95 1.59E-01 3.00E-01
17343170 Trefoil factor 2 (spasmolytic protein 1) Tff2 6.75 1.52E-01 2.96E-01
17253215 Solute carrier family 6 (neurotransmitter transporter) Slc6a4 5.25 1.44E-03 8.48E-03
17458514 Neuropeptide Y Npy 4.97 5.66E-04 5.65E-03
17344943 Cysteine-rich secretory protein 3 Crisp3 4.55 2.05E-01 3.22E-01
17483925 Deleted in malignant brain tumors 1 Dmbt1 4.32 3.51E-01 3.78E-01
17318815 Apolipoprotein L 11b Apol11b 4.17 5.74E-02 1.64E-01
17495622 Glycoprotein 2 (zymogen granule membrane) Gp2 4.09 1.93E-01 3.18E-01
17268243 Beta-1,4-N-acetyl-galactosaminyl transferase 2 B4galnt2 4.08 2.31E-01 3.36E-01
17481378 Cholecystokinin B receptor Cckbr 4.00 1.03E-04 1.71E-03
17275015 Anterior gradient 2 (Xenopus laevis) Agr2 3.98 2.41E-01 3.45E-01
17467973 Regenerating islet-derived 3 gamma Reg3g 3.96 1.48E-01 2.96E-01
17354074 G protein-coupled receptor 151 Gpr151 3.81 4.54E-04 5.04E-03
17517097 RIKEN cDNA 1600029D21 gene 1600029D21Rik 3.65 9.46E-02 2.36E-01
17225224 Endothelin converting enzyme-like 1 Ecel1 3.59 1.37E-03 8.48E-03
17251091 Myosin, heavy polypeptide 4, skeletal muscle Myh4 3.58 1.01E-01 2.47E-01
17522555 Lactotransferrin Ltf 3.50 3.18E-01 3.70E-01
17334172 Demilune cell and parotid protein 2 Dcpp2 3.49 2.06E-01 3.22E-01
17266851 Schlafen 9 Slfn9 3.33 1.55E-02 5.52E-02
17358749 Lipase, family member N Lipn 3.32 1.34E-03 8.48E-03
17497525 A disintegrin and metallopeptidase domain 8 Adam8 3.29 6.22E-04 5.65E-03
17459309 Immunoglobulin kappa variable 14-126 Igkv14-126 3.17 1.09E-01 2.60E-01
17216960 Polymeric immunoglobulin receptor Pigr 3.13 1.73E-01 3.09E-01
17358724 Lipase, gastric Lipf 3.10 3.51E-01 3.78E-01
17524311 Mucin 16 Muc16 2.91 1.62E-01 3.01E-01
17245231 Lysozyme 1 Lyz1 2.83 4.82E-01 4.92E-01
17438684 Odontogenic, ameloblast asssociated Odam 2.83 2.32E-01 3.36E-01
17496211 ATPase, Caþþ transporting, cardiac muscle, fast twitch 1 Atp2a1 2.77 2.88E-01 3.54E-01
17378149 BPI fold containing family B, member 1 Bpifb1 2.74 3.50E-01 3.78E-01
17463338 Fibroblast growth factor 23 Fgf23 2.68 6.46E-03 2.58E-02
17392255 Fibronectin leucine rich transmembrane protein 3 Flrt3 2.66 2.22E-04 3.17E-03
17318083 Lymphocyte antigen 6 complex, locus A Ly6a 2.56 1.91E-02 6.24E-02
17438963 Pro-platelet basic protein Ppbp 2.56 3.88E-01 4.04E-01
17500195 Steroidogenic acute regulatory protein Star 2.55 1.28E-03 8.48E-03
17270162 Solute carrier family 4 (anion exchanger), member 1 Slc4a1 2.49 3.69E-01 3.93E-01
17531701 Predicted gene, 20317 Gm20317 2.48 1.79E-01 3.14E-01
17296344 Follistatin Fst 2.46 3.95E-03 1.88E-02
17314373 Mucin 19 Muc19 2.42 2.01E-01 3.22E-01
17254295 Extracellular proteinase inhibitor Expi 2.41 4.37E-01 4.51E-01
17284507 Immunoglobulin heavy chain (gamma polypeptide) Ighg 2.40 1.66E-01 3.01E-01
17474621 Creatine kinase, muscle Ckm 2.40 2.94E-01 3.54E-01
17273304 Carbonyl reductase 2 Cbr2 2.36 1.23E-01 2.73E-01
17337458 Tripartite motif-containing 10 Trim10 2.35 1.53E-01 2.96E-01
17467316 Growth arrest and DNA-damage-inducible 45 alpha Gadd45a 2.34 9.45E-04 7.47E-03
17509565 Annexin A10 Anxa10 2.33 1.01E-02 3.88E-02
17547647 Predicted gene 9241 Gm9241 2.30 1.93E-02 6.24E-02
Downregulated
17491349 MAS-related GPR, member B5 Mrgprb5 0.45 3.89E-02 3.89E-02
17479944 Olfactory receptor 295 Olfr295 0.49 1.74E-02 3.48E-02
Note: The top 50 upregulated and two downregulated genes at the three-day time point after TIC injury are shown compared to the naı̈ve control group
with their p values and a false discovery rate of 5% (q value; n¼ 6 per group). Bold font indicates genes uniquely expressed on Day 3 but not on Day 21.
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Table 2. Genes differentially regulated >50% 21 days post-TIC injury.
Transcript ID Gene assignment Gene symbol
TIC/naı̈ve
ratio p Values q Values
Upregulated
17407412 Small proline-rich protein 1A Sprr1a 15.44 4.46E-04 1.12E-02
17244601 Neurotensin Nts 4.69 1.32E-03 1.89E-02
17231033 Activating transcription factor 3 Atf3 2.74 9.49E-04 1.58E-02
17481378 Cholecystokinin B receptor Cckbr 2.72 9.17E-04 1.58E-02
17360942 Galanin Gal 2.40 3.76E-02 7.10E-02
17219639 Olfactory receptor 418, pseudogene 1 Olfr418-ps1 2.25 2.05E-03 2.28E-02
17362953 Membrane-spanning 4-domains,
subfamily A, member 7
Ms4a7 2.16 2.78E-03 2.53E-02
17273694 Pro-opiomelanocortin-alpha Pomc 2.06 4.60E-01 4.70E-01
17225224 Endothelin converting enzyme-like 1 Ecel1 2.00 3.19E-02 6.77E-02
17463619 Proline rich protein 2 Prp2 1.86 1.38E-01 1.75E-01
17266851 Schlafen 9 Slfn9 1.83 1.62E-01 1.86E-01
17500195 Steroidogenic acute regulatory protein Star 1.83 1.43E-02 4.76E-02
17421521 Predicted gene 13154 Gm13154 1.79 1.66E-04 1.08E-02
17449585 Betacellulin, epidermal growth
factor family member
Btc 1.77 2.87E-04 1.08E-02
17318083 Lymphocyte antigen 6 complex, locus A Ly6a 1.76 1.16E-01 1.52E-01
17264835 CD68 antigen Cd68 1.76 2.87E-02 6.74E-02
17366355 Component of Sp100-rs Csprs 1.72 3.62E-02 7.05E-02
17497637 Olfactory receptor 524 Olfr524 1.71 2.10E-02 5.82E-02
17285677 Histone cluster 1, H2ao Hist1h2ao 1.71 6.48E-03 3.79E-02
17532710 Predicted gene 14347 Gm14347 1.67 7.65E-03 3.82E-02
17491349 MAS-related GPR, member B5 Mrgprb5 1.67 1.51E-01 1.80E-01
17458960 Vomeronasal 1 receptor 20 Vmn1r20 1.66 7.18E-02 1.04E-01
17494710 Olfactory receptor 707 Olfr707 1.65 2.78E-02 6.74E-02
17458439 Glycoprotein (transmembrane) nmb Gpnmb 1.65 2.44E-02 6.41E-02
17230078 Myeloid cell nuclear differentiation antigen Mnda 1.65 1.71E-01 1.86E-01
17525471 Predicted gene 3434 Gm3434 1.63 7.33E-03 3.82E-02
17548752 Transmembrane protein 202 Tmem202 1.61 4.93E-02 8.22E-02
17286434 Serine (or cysteine) peptidase inhibitor,
clade B, member 9g
Serpinb9g 1.61 2.57E-02 6.43E-02
17387662 Olfactory receptor 1054 Olfr1054 1.60 6.03E-02 9.42E-02
17358749 Lipase, family member N Lipn 1.60 9.59E-02 1.31E-01
17358832 Interferon-induced protein with
tetratricopeptide repeats 1
Ifit1 1.60 3.32E-02 6.77E-02
17242322 Predicted gene 9507 Gm9507 1.59 6.19E-03 3.79E-02
17544295 Serine-rich, secreted, X-linked Srsx 1.59 1.03E-01 1.37E-01
17483192 Seizure related 6 homolog like 2 Sez6l2 1.59 4.81E-01 4.84E-01
17331258 Olfactory receptor 197 Olfr197 1.59 1.78E-03 2.22E-02
17546316 Eukaryotic translation initiation
factor 2, subunit 3
Eif2s3y 1.58 1.55E-01 1.82E-01
17285746 Histone cluster 1, H2bn Hist1h2bn 1.58 6.99E-02 1.04E-01
17545543 Predicted gene 16390 Gm16390 1.57 3.01E-02 6.74E-02
17429512 MicroRNA 30c-1 Mir30c-1 1.57 2.53E-01 2.61E-01
17489547 Predicted gene 6725 Gm6725 1.57 2.01E-02 5.81E-02
17244563 Citrate synthase like Csl 1.56 1.57E-02 4.91E-02
17263765 Solute carrier family 47, member 1 Slc47a1 1.56 2.14E-01 2.27E-01
17212364 RIKEN cDNA 1500015O10 gene 1500015O10Rik 1.55 1.38E-01 1.75E-01
17217048 RIKEN cDNA 5430435G22 gene 5430435G22Rik 1.55 6.03E-03 3.79E-02
17533462 Predicted gene 5382 Gm5382 1.55 1.63E-01 1.86E-01
17467108 LSM5 homolog, U6 small nuclear
RNA associated (S. cerevisiae)
Lsm5 1.54 2.46E-03 2.46E-02
17477055 Expressed sequence EU599041 EU599041 1.53 7.16E-02 1.04E-01
17407400 Small proline-rich protein 1B Sprr1b 1.52 1.48E-02 4.77E-02
17448676 Predicted gene 5868 Gm5868 1.52 4.25E-02 7.58E-02
17500702 A disintegrin and metallopeptidase
domain 25 (testase 2)
Adam25 1.52 9.92E-03 4.06E-02
(continued)
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Table 2. Continued
Transcript ID Gene assignment Gene symbol
TIC/naı̈ve
ratio p Values q Values
Downregulated
17483925 Deleted in malignant brain tumors 1 Dmbt1 0.11 1.77E-01 4.03E-01
17245231 Lysozyme 1 Lyz1 0.12 1.68E-01 4.03E-01
17358724 Lipase, gastric Lipf 0.14 1.27E-01 4.03E-01
17378149 BPI fold containing family B, member 1 Bpifb1 0.16 1.07E-01 4.03E-01
17522555 Lactotransferrin Ltf 0.18 1.83E-01 4.03E-01
17254295 Extracellular proteinase inhibitor Expi 0.18 1.51E-01 4.03E-01
17485098 Mucin 5, subtype B, tracheobronchial Muc5b 0.20 2.30E-01 4.03E-01
17305520 Eosinophil-associated, ribonuclease
A family, member 1
Ear1 0.20 2.71E-01 4.03E-01
17343170 Trefoil factor 2 (spasmolytic protein 1) Tff2 0.24 2.66E-01 4.03E-01
17502789 Glycophorin A Gypa 0.27 2.85E-01 4.03E-01
17408897 Chitinase 3-like 3 Chi3l3 0.30 2.89E-01 4.03E-01
17268243 Beta-1,4-N-acetyl-galactosaminyl transferase 2 B4galnt2 0.32 3.19E-01 4.03E-01
17326075 Resistin like gamma Retnlg 0.33 2.50E-01 4.03E-01
17312219 Lymphocyte antigen 6 complex, locus G Ly6g 0.34 3.49E-01 4.03E-01
17399823 S100 calcium binding protein A8 (calgranulin A) S100a8 0.34 3.40E-01 4.03E-01
17407363 S100 calcium binding protein A9 (calgranulin B) S100a9 0.35 2.65E-01 4.03E-01
17495622 Glycoprotein 2 (zymogen granule membrane) Gp2 0.35 3.23E-01 4.03E-01
17270162 Solute carrier family 4 (anion exchanger),member 1 Slc4a1 0.35 3.10E-01 4.03E-01
17522369 Neutrophilic granule protein Ngp 0.36 3.51E-01 4.03E-01
17337706 Rhesus blood group-associated A glycoprotein Rhag 0.36 1.71E-01 4.03E-01
17496211 ATPase, Caþþ transporting, cardiac muscle, fast twitch 1 Atp2a1 0.37 2.94E-01 4.03E-01
17275015 Anterior gradient 2 (Xenopus laevis) Agr2 0.37 3.89E-01 4.11E-01
17251046 Myosin, heavy polypeptide 1, skeletal muscle, adult Myh1 0.38 3.71E-01 4.08E-01
17350267 Myotilin Myot 0.38 2.29E-01 4.03E-01
17284354 Immunoglobulin heavy chain (J558 family) Igh-VJ558 0.39 2.14E-01 4.03E-01
17371296 Xin actin-binding repeat containing 2 Xirp2 0.39 1.64E-01 4.03E-01
17485246 Troponin T3, skeletal, fast Tnnt3 0.40 2.88E-01 4.03E-01
17303874 Myozenin 1 Myoz1 0.40 2.41E-01 4.03E-01
17372662 Proteoglycan 2, bone marrow Prg2 0.41 2.81E-01 4.03E-01
17396152 Carbonic anhydrase 3 Car3 0.41 2.98E-01 4.03E-01
17424880 Predicted gene, 19980 Gm19980 0.41 1.01E-01 4.03E-01
17235011 Elastase, neutrophil expressed Elane 0.41 3.23E-01 4.03E-01
17497704 Cytochrome c oxidase, subunit VIIIb Cox8b 0.42 5.12E-02 4.03E-01
17232453 Triadin Trdn 0.42 2.19E-01 4.03E-01
17246412 Olfactory receptor 773 Olfr773 0.42 2.52E-02 4.03E-01
17474621 Creatine kinase, muscle Ckm 0.43 3.07E-01 4.03E-01
17243910 Myosin binding protein C, slow-type Mybpc1 0.43 2.22E-01 4.03E-01
17514553 Matrix metallopeptidase 8 Mmp8 0.44 3.49E-01 4.03E-01
17531482 Cathelicidin antimicrobial peptide Camp 0.45 3.93E-01 4.11E-01
17438963 Pro-platelet basic protein Ppbp 0.45 4.64E-01 4.64E-01
17284334 Immunoglobulin heavy chain (gamma polypeptide) Ighg 0.45 1.68E-01 4.03E-01
17365803 Nebulin-related anchoring protein Nrap 0.45 9.83E-02 4.03E-01
17490245 Myosin binding protein C, fast-type Mybpc2 0.45 1.72E-01 4.03E-01
17385099 Nebulin Neb 0.46 1.73E-01 4.03E-01
17487759 CD177 antigen Cd177 0.46 2.38E-01 4.03E-01
17302279 Olfactomedin 4 Olfm4 0.46 2.44E-01 4.03E-01
17214476 Desmin Des 0.47 1.84E-01 4.03E-01
17229851 calsequestrin 1 Casq1 0.47 1.23E-01 4.03E-01
17484587 Cytochrome P450, family 2,
subfamily e, polypeptide 1
Cyp2e1 0.47 3.60E-01 4.03E-01
17294816 Creatine kinase, mitochondrial 2 Ckmt2 0.47 1.58E-01 4.03E-01
Note: The top 50 upregulated and downregulated genes at the 21-day time point after TIC injury are shown compared to the naı̈ve control group with their
p values and a false discovery rate of 5% (q value; n¼ 6 per group). TIC: trigeminal nerve injury. Bold font indicates genes uniquely expressed on Day 21 but
not on Day 3.
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(h)) and non-neuronal profiles (Figure 2(j) and (k)). The
H3K9ac protein, as determined by immunofluorescence
staining, was expressed predominately in medium- and
small-sized neurons (Figure 2(g) and (h)). At 3-day post-
injury time point, the percentage of H3K9ac-positive
neurons did not differ significantly from that of the
naı̈ve group (80.1% of total neurons after TIC injury
vs. 83.5% of total neurons in naı̈ve mice; n¼ 3 per
group, p> 0.05; total neuron count¼ 10,019) (Figure 2
(i), top). In contrast, the percentage of H3K9ac-positive
neurons decreased significantly (41.5% of total neurons
in the ipsilateral TG after TIC vs. 78% of total neurons
in naı̈ve mice; n¼ 3 per group, p  0.01; total neuron
count¼ 6,890) at day 21 post-nerve injury (Figure 2(i),
bottom). The percentage of total neurons expressing
H3K9ac on the contralateral side TG in mice with TIC
injury was not significantly different from that of naı̈ve
mice (data not shown). These data provide clear evi-
dence of epigenetic modulation in the TG limited to
the side of the TIC injury persisting at day 21 post-
nerve injury time point.
Minimal dual labeling of H3K9ac in TG satellite glial cells. To
further investigate the acetylation of H3K9 in non-
Table 3. Overlapping gene ontology for days 3 and 21 post-TIC.
Gene ontology
Number
of genes
Gene
Symbol
Regulated
expression day 3
Regulated
expression day 21
Nerve regeneration/peptide cross-linking 1 Sprr1a Upregulated Upregulated
Inflammatory response 2 Gal Upregulated Upregulated
Ppbp Upregulated Downregulated
Chemokine-mediated signaling pathway 2 Tff2 Upregulated Downregulated
Ppbp Upregulated Downregulated
Immune system process 2 Ltf Upregulated Downregulated
Bpifb1 Upregulated Downregulated
Innate immune response 3 Dmbt1 Upregulated Downregulated
Bpifb1 Upregulated Downregulated
Ighg Upregulated Downregulated
Defense response to bacterium 3 Muc5b Upregulated Downregulated
Lyz1 Upregulated Downregulated
Ighg Upregulated Downregulated
Ion transport 2 Ltf Upregulated Downregulated
Slc4a1 Upregulated Downregulated
Neuropeptide signaling pathway 2 Gal Upregulated Upregulated
Ecel1 Upregulated Upregulated
Nts Upregulated Upregulated
G-protein-coupled receptor signaling pathway 3 Cckbr Upregulated Upregulated
Ppbp Upregulated Downregulated
Mrgprb5 Downregulated Upregulated
Signal transduction 2 Cckbr Upregulated Upregulated
Mrgprb5 Downregulated Upregulated
Positive regulation of transcription by RNA polymerase II 2 Gal Upregulated Upregulated
Atf3 Upregulated Upregulated
Positive regulation of gene expression 3 Atf3 Upregulated Upregulated
Agr2 Upregulated Downregulated
Star Upregulated Upregulated
Positive regulation of cell proliferation 3 Atf3 Upregulated Upregulated
Tff2 Upregulated Downregulated
Cckbr Upregulated Upregulated
Biological process 2 Slfn9 Upregulated Upregulated
Lipn Upregulated Upregulated
Proteolysis 2 Ecel1 Upregulated Upregulated
Ltf Upregulated Downregulated
Lipid catabolic process 2 Lipn Upregulated Upregulated
Lipf Upregulated Downregulated
Lipid metabolic process 2 Lipn Upregulated Upregulated
Lipf Upregulated Downregulated
Seventeen gene ontologies were found in common for days 3 and 21 post-TIC.
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neuronal cells, the satellite glial cells of TG were dual
stained. For positive identification of satellite glial cells,
an antibody for the glial marker glutamine synthetase
(GS) was used. This key enzyme catalyzes the amidation
of glutamate to glutamine.
Its localization is restricted to glia cells in the
brain,24–26 as well as satellite glial cells and Schwann
cells in DRG and TG sensory ganglia.27–30
Neurons in the TG are sensory homologues to
those of the DRG. To identify the relative size distribu-
tion of TG neurons in naı̈ve mice, the diameters
were analyzed using MetaMorph offline software
(5,119 neurons, n¼ 4). Based on diameter, three
groups of neurons were classified as small (<20 mm)
with 9.9% frequency, medium (20–40 mm) with 83.4%
frequency, or large (>40 mm) with 6.7% frequency.
About 93% of neurons in the TG are small-sized neu-
rons (<20 mm) and medium-sized neurons (20–40mm)
which likely mediate nociception and would require
increased synthesis of the neuropeptides and neurotrans-
mitters released in pathological conditions. The smallest
diameter neurons were 11 mm. The maximum diameter
of the large-sized TG neurons was 60 mm which was
slightly smaller than that of neurons in the DRG.29
Occasionally, neurons with diameters of > 61 mm were
observed (0.12% frequency). Neuron sizes in mice were
similar to those previously reported for TG of mice and
Wistar rats, except unlike the rat which is reported to
have more larger neurons and have more in the left TG
than the right,30 similar percentage distributions were
observed on left and right sides of these study mice
(Figure 2, bottom).
HDACi’s prevented development of mechanical
hypersensitivity
The fact that global acetylation of H3K9 was decreased
in ipsilateral TG neurons 21 days post-TIC injury sug-
gested that reduced H3K9 acetylation contributes to the
observed dysregulated gene expression resulting in per-
sistence of pain. Therefore, we explored whether inhibit-
ing histone deacetylase (HDAC) activity would block
Table 4. KEGG pathways.
Term Count Gene Symbols p Value
Three days post-TIC
mmu04713:Circadian entrainment 18 Adcy1, Adcy5, Adcy8, Calm4, Camk2a, Camk2b, Gnai1, Gnai2,
Gnaq, Gnb2, Gria3, Gria4, Grin1, Grin2a, Itpr1, Plcb1,
Plcb3, Prkg2
1.80E-04
mmu04080:Neuroactive
ligand-receptor interaction
36 Adra2c, Avpr1a, C3ar1, Cckar, Cckbr, Chrm2, Chrm5, Chrna6,
Cysltr2, F2r, Gabra6, Gabrb2, Gabrg2, Gria3, Gria4, Grin1,
Grin2a, Grin3a, Htr1f, Htr4, Lpar3, Ltb4r2, Mc2r, Mc4r, P2rx2,
P2ry13, P2ry6, Ptgdr, Ptgir, S1pr1, S1pr2, Taar2, Taar7e, Taar8b,
Taar9, Thra
2.06E-04
mmu04015:Rap1 signaling pathway 29 Adcy1, Adcy5, Adcy8, Calm4, Csf1, Csf1r, F2r, Fgf11, Fgf2, Fgf23,
Fgf3, Figf, Gnai1, Gnai2, Gnaq, Grin1, Grin2a, Hgf, Igf1r, Itgb1,
Lpar3, Lpar5, Magi2, Pard6a, Pfn1, Plcb1, Plcb3, Rac1, Tln2
3.14E-04
mmu04724:Glutamatergic synapse 19 Adcy1, Adcy5, Adcy8, Gls, Gnai1, Gnai2, Gnaq, Gnb2, Gria3,
Gria4, Grin1, Grin2a, Grin3a, Homer1, Itpr1, Plcb1, Plcb3,
Pld2, Slc1a7
4.41E-04
mmu04971:Gastric acid secretion 14 Adcy1, Adcy5, Adcy8, Calm4, Camk2a, Camk2b, Cckbr, Gnai1,
Gnai2, Gnaq, Itpr1, Plcb1, Plcb3, Sst
6.88E-04
mmu04723:Retrograde
endocannabinoid signaling
17 Adcy1, Adcy5, Adcy8, Faah, Gabra6, Gabrb2, Gabrg2, Gnai1,
Gnai2, Gnaq, Gnb2, Gria3, Gria4, Itpr1, Plcb1, Plcb3, Rims1
9.83E-04
mmu00100:Steroid biosynthesis 7 Cyp24a1, Dhcr24, Dhcr7, Ebp, Lss, Soat1, Soat2 9.90E-04
mmu04720:Long-term potentiation 13 Adcy1, Adcy8, Calm4, Camk2a, Camk2b, Gnaq, Grin1, Grin2a,
Itpr1, Plcb1, Plcb3, Rps6ka1, Rps6ka2
1.03E-03
mmu04540:Gap junction 15 Adcy1, Adcy5, Adcy8, Gnai1, Gnai2, Gnaq, Itpr1, Plcb1, Plcb3,
Prkg2, Tuba1c, Tubb2b, Tubb3, Tubb5, Tubb6
1.26E-03
mmu04925:Aldosterone
synthesis and secretion
15 Adcy1, Adcy5, Adcy8, Calm4, Camk1, Camk2a, Camk2b, Gnaq,
Hsd3b1, Itpr1, Mc2r, Plcb1, Plcb3, Prkce, Star
1.26E-03
21 Days post-TIC
mmu04910:Insulin signaling pathway 14 Phkg1, Rps6kb1, Pck1, Srebf1, Lipe, Trip10, Pik3r2, Hk1, Socs4,
Acacb, Phka1, Sh2b2, Rheb, Fasn
9.64E-03
Note: Genes associated with the top 10 enriched KEGG pathways at days 3 and 21. Note that the upregulated genes are underlined in the third column of
the table. KEGG: Kyoto Encyclopedia of Genes and Genomes.
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the development of mechanical hypersensitivity after
TIC nerve injury. In the second cohort, the time course
of whisker pad hypersensitivity was tested through day
28 post-TIC nerve injury. Two class I HDACi’si, SAHA
and MS-275, were used to determine their effect on the
hypersensitized responses to the ipsilateral whisker pad
stimulation. Figure 3 shows the average mechanical
threshold of the ipsilateral side whisker pad for the
cohort receiving daily HDACi treatments initiated five
days before and continued seven days after TIC surgery.
The initial average baseline threshold values of all mice
was 2.60 0.54 g. Mice were then distributed evenly to
treatment groups, such that all groups consisted of three
mice with high baselines and two with moderate base-
lines (n¼ 5 per group). The mechanical threshold after
TIC injury of the vehicle-treated group decreased 98%
Table 5. Top 10 biological process and molecular function terms.
Term Count p Value
Three days post-TIC injury-enriched “biological process” terms of differentially expressed genes
GO:0007399nervous system development 44 4.38E-04
GO:0045124regulation of bone resorption 5 1.13E-03
GO:0050790regulation of catalytic activity 8 1.26E-03
GO:0051262protein tetramerization 10 1.31E-03
GO:0007165signal transduction 112 1.42E-03
GO:0007264small GTPase mediated signal transduction 29 2.32E-03
GO:0016197endosomal transport 9 3.18E-03
GO:0051260protein homooligomerization 25 3.27E-03
GO:0000186activation of MAPKK activity 8 3.76E-03
GO:0034765regulation of ion transmembrane transport 19 3.93E-03
Three days post-TIC injury enriched "molecular function” terms of differentially expressed genes
GO:0043236laminin binding 9 2.16E-04
GO:0005216ion channel activity 25 4.52E-04
GO:0042803protein homodimerization activity 79 5.48E-04
GO:0005251delayed rectifier potassium channel activity 9 1.01E-03
GO:0071933Arp2/3 complex binding 5 1.96E-03
GO:0005244voltage-gated ion channel activity 19 3.84E-03
GO:0004871signal transducer activity 62 4.93E-03
GO:0051015actin filament binding 18 7.43E-03
GO:1901981phosphatidylinositol phosphate binding 4 8.68E-03
GO:0001664G-protein-coupled receptor binding 11 1.00E-02
21 Days post-TIC injury enriched “biological process” terms of differentially expressed genes
GO:0048566embryonic digestive tract development 6 1.15E-03
GO:0016477cell migration 20 1.65E-03
GO:0007049cell cycle 45 3.55E-03
GO:0014044Schwann cell development 4 9.63E-03
GO:0007283spermatogenesis 31 9.91E-03
GO:0035458cellular response to interferon-beta 7 1.16E-02
GO:1902953positive regulation of ER to Golgi vesicle-mediated transport 3 1.24E-02
GO:0006364rRNA processing 13 1.53E-02
GO:0035457cellular response to interferon-alpha 4 1.65E-02
GO:0032868response to insulin 9 1.77E-02
21 Days post-TIC injury enriched “molecular function” terms of differentially expressed genes
GO:0046872metal ion binding 185 1.53E-02
GO:0005525GTP binding 29 1.59E-02
GO:0003676nucleic acid binding 76 1.67E-02
GO:0005515protein binding 219 2.62E-02
GO:0046974histone methyltransferase activity (H3-K9 specific) 3 2.97E-02
GO:0043237laminin-1 binding 3 2.97E-02
GO:0003700transcription factor activity, sequence-specific DNA binding 55 3.39E-02
GO:0000977RNA polymerase II regulatory region sequence-specific DNA binding 18 3.46E-02
GO:0019789SUMO transferase activity 4 3.76E-02
GO:0004252serine-type endopeptidase activity 17 4.56E-02
Note: Post-TIC injury differentially expressed genes at days 3 and 21 were enriched for the indicated processes and functions.
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Figure 2 Trigeminal nerve injury leads to significant decrease in H3K9 acetylation of trigeminal ganglia (TG) neurons 21 days after injury
compared to naı̈ves. Expression of H3K9ac (a, green) and neuronal marker NeuN (b, red) in TG neurons of a naı̈ve mouse is shown as a
merged image in (c). Expression of H3K9ac (d) and NeuN (e) in TG of a mouse with TIC nerve injury at the 21-day time point is shown as
a merged image in (f). Neurons double labeled with H3K9ac appear orange (white arrows). Enlarged images in (g) and (h) are from the
framed areas in panels (c) and (f), respectively. The bar graph (i) shows the percentage of TG neurons expressing H3K9ac (n¼ 3 per group,
6890 neurons counted) (*** p  0.01, t-test). Scale bar¼ 200 lm. H3K9ac in non-neuronal TG cells. H3K9ac immunoreactivity was
localized on the nuclei of neurons and non-neuronal structures (red). Satellite glial cells (and potentially epithelial cells and Schwann cells)
were stained for glutamine synthetase in the TG (green). Example of dual labeling of H3K9ac (red) and non-neuronal marker glutamine
synthetase (green) in TG from a naı̈ve mouse (j) and a TIC injury mouse (k) at 21 days. Some of the satellite glial cells are indicated with
white arrows. H3K9ac immunoreactivity visually appears more prevalent in TG from naı̈ve mice than in the trigeminal nerve-injured mice.
Bar¼ 100 mm. Nerve injury decreases H3K9ac, alters transcription, and can increase pain. The summary diagram (l) depicts the rela-
tionship of nerve injury pain to H3K9ac decrease, altered transcription, and resultant further increase in pain. Trigeminal ganglia neuronal
counts and size distribution in mice. A total of 5119 TG neurons were counted and measured from three naı̈ve mice (m). The data show
the similarity in the size distribution for the left and right TG in the male BALB/C mice. TIC: trigeminal nerve injury.
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to 0.052 0.03 g on day 3 post-nerve injury, indicating
increased hypersensitivity due to the nerve injury. Their
decreased mechanical threshold continued through day
28 post-surgery (0.05 0.019 g). Responses of two naı̈ve
mice receiving vehicle, serving only as comparison to the
three TIC groups, did not fluctuate from baseline levels
through day 28 post-surgery.
Beginning three days post-surgery, mice with TIC
nerve injury treated pre-emptively with the SAHA
HDACi had reduced mechanical thresholds as well as
on day 7 post-surgery (0.66 0.20 g) (Figure 3). By
day 14, mechanical thresholds significantly increased
(1.27 0.15 g) and remained elevated through day 21
(1.17 0.11 g), indicating attenuation of the mechanical
hypersensitivity. By day 28 post-nerve injury, the
mechanical thresholds were equivalent to the vehicle
control group without TIC (2.07 0. 0.39 g, p> 0.05;
two-way ANOVA, Tukey’s multiple comparisons test).
Compared to the vehicle-treated TIC injury group, this
was a statistically significant increase in the mechanical
threshold (p  0.01; two-way ANOVA, Tukey’s multiple
comparisons test; n¼ 5 per group).
Mechanical thresholds in mice with TIC injury
treated pre-emptively with MS275 remained near pre-
surgery baseline thresholds similar to the other groups
(2.60 0.54 g; n¼ 5 per group) (Figure 3). While a
decreased mechanical threshold (0.24 0.13 g) was evi-
dent on day 3 post-surgery indicating that the TIC injury
procedure was successful, the mechanical threshold was
increased to 2.39 0.44 g on post-surgery day 28. The
final average threshold was similar to naı̈ve mice (2.50
 0.50 g, p> 0.05; two-way ANOVA, Tukey’s multiple
comparisons test). The mechanical threshold for the
MS275-treated group was significantly increased com-
pared to vehicle-treated TIC injury mice (p  0.001).
qPCR authentication with and without HDACi’s
Authentication by qPCR demonstrated that average
Sprr1a, Gal, and Atf3 gene expression levels three-days
post-TIC were increased 650-, 116- and 22-fold; and they
were increased 206-, 4.8- and 4.8-fold 21 days post-TIC
(Figure 4). In addition to Gal, other neuropeptides, neu-
rotensin (Nts), and neuropeptide Y (Npy) were increased
post-TIC injury> seven- and fourfold, respectively, after
three days. By 28 days, relative gene expression for Gal
and Atf3 in mice with TIC was the same as in naı̈ve mice
with or without HDACi’s, while Sprr1a remained elevat-
ed 10-fold.
Discussion
An important finding is that preemptive administration
of two HDACi’s, SAHA and MS-275, prevented devel-
opment of persistent mechanical hypersensitivity after
trigeminal nerve injury. In the present study, the TIC
Figure 3. Effect of preemptive HDAC inhibitors on mechanical thresholds. The average 50% mechanical thresholds were determined for
the ipsilateral side whisker pads of mice TIC injury with/without HDAC inhibitor treatment. Responses over time for each of the three
initially matched groups (i.e. vehicle, SAHA and MS275; n¼ 5 per group) were compared to baseline. By day 21 and 28, the mechanical
thresholds of mice with TIC injury treated preemptively with SAHA or MS275 were no longer significantly decreased compared to
baseline levels and were significantly different from mice with TIC treated with vehicle. Note that symbols of significance for vehicle and
MS275 groups are located below data points while those for SAHA are located above (n = 5 per group, *¼ vs. baseline; #¼ vs. TIC +
vehicle; *p < 0.05; **p < 0.01; ***p <0.001; #p < 0.05; ##p < 0.01; ###p<0.001, two-way ANOVA, Tukey’s multiple comparisons test).
SAHA: suberanilohydroxamic acid.
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nerve injury mouse model was also employed to deter-
mine the expression and epigenetic modifications in TG
associated with orofacial neuropathic pain at two time
points. Following TIC injury, RAG genes were upregu-
lated early in the course of injury repair, and remained
upregulated three weeks post-TIC injury. qPCR deter-
mined that Sprr1a mRNA expression which was greatly
elevated 3,650-fold three days after nerve injury
remained elevated at 28 days, while expression of the
two RAGs, Atf3 and Gal, had returned to control
levels. Although no detectable change in global acetyla-
tion of H3K9 was evident on day 3, it was significantly
decreased in ipsilateral TG neurons by day 21. The most
straightforward interpretation is that differentially
expressed genes at day 3 are not yet affected but by
day 21 are likely affected by cumulative histone deace-
tylation. Several common and many uniquely expressed
genes were discovered in the TG comparing the day 3
and day 21 post-nerve injury time points. These findings
are consistent with a windup phase of histone deacety-
lation during the first three weeks following TIC injury
and indicate TG neurons are receptive to epigenetic
modifications that may be associated with critical
aspects of the pain response.
Animal model to examine epigenetic changes
over time
The TIC nerve injury mouse model is ideal to determine
epigenetic changes over time. The model was devised to
Figure 4. Relative mRNA levels are shown at days 3, 21, and 28 for Sprr1a (a), Gal (b), and Atf3 (c) in TG from mice with and without
TIC, with and without the HDAC inhibitors or vehicle. The gene expression at days 3 and 21 is in contrast to day 28. By 28 days, relative
gene expression for Gal and Atf3 in mice with TIC was the same as in naı̈ve mice with or without HDACi’s, while Sprr1a remained elevated
10-fold. SAHA: suberanilohydroxamic acid; TIC: trigeminal nerve injury.
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provide a reliable model of orofacial neuropathic pain
developing quickly and persisting long term.14,15 The
decrease in mechanical threshold induced on the whisker
pad ipsilateral to the TIC injury indicates an increase in
mechanical hypersensitivity or allodynia. The hypersen-
sitivity persists steadily through the 28-day trial without
recovery. Both whisker pads of the naı̈ve mice as well as
the contralateral side whisker pad in mice with TIC
injury show no mechanical threshold changes further
indicating the effectiveness and reliability of the TIC
model. Our previous studies document the decrease in
the mechanical threshold can persist at least through
week 21 after TIC injury.14
Differential gene expression in the ipsilateral
trigeminal ganglia post-TIC nerve injury
It is interesting to speculate that epigenetic mechanisms
contribute to the continued overexpression of these
genes long after others have returned to constitutive
levels and may be contributing to persistent pain
states. Several genes were differentially expressed in
TGs after TIC injury at both the 3- and 21-day time
points reflecting the dysregulation in this orofacial neu-
ropathic pain model. A number of published microarray
studies have addressed similar gene expression patterns
in DRG after sciatic nerve injury.31–34 Genes typically
dysregulated in pain conditions including injury bio-
markers (e.g. Atf3 and Sprr1a) and neuropeptides (Gal
and Npy) were also expressed in the TIC model after
trigeminal nerve injury. Not unexpectedly since gluta-
mate is a key pain neuroactivator, dysregulated genes
associated with glutamatergic synapses, long-term
potentiation, gap junction, and neuroactive ligand–
receptor interactions were abundant in the KEGG path-
way analysis. Several studies have identified gene expres-
sion in TG of both humans and rodents35–37; however,
sequential expression over time after trigeminal nerve
injury has not been reported. One point made in these
previous studies is that the gene expression in TG is
unique in comparison to DRG, particularly in the
human for expression of migraine genes.
Genes encoding inflammatory mediators (Cd68, Ccl2,
Cxcl10, Cxcl13), ion channel subunits (e.g. Cacna2d1,
Kcnc2), and growth factors (Vgf) are also reported to
increase after peripheral nerve injury. Interestingly,
other inflammatory cell-related genes (CD177, Igkv14-
126, IgLy6a, Ly6a, Ighg) not reported previously were
expressed after trigeminal nerve injury.
Biological processes and functions of differentially
expressed genes
Three days post-TIC nerve injury. Thirty-two genes were sig-
nificantly (p< 0.05) upregulated in ipsilateral TG genes
three days post-TIC injury. The three most upregulated
genes, Sprr1a (up 174-fold), Gal (up 26-fold), and Atf3
(up 8-fold), are nerve RAGs that are activated following
peripheral nerve injury.38
Atf3, a member of the ATF/CREB family of basic
leucine zipper domain (bZIP) transcription factors, is
normally expressed at low levels but is rapidly activated
in sensory, sympathetic, and motor neurons by stress
stimuli after peripheral nerve injury, but not after central
injury which has much less reparative ability.39,40
Overexpression of Atf3, as part of the inducible nerve
RAG response, along with its “effector” RAGs, Sprr1a,
and Gal, has been observed previously following both
facial nerve damage41 and sciatic nerve injury42 in mice.
Atf3 mutant mice have decreased neurite outgrowth on
primary DRG neurons.41
Sprr1a is one of a group of epithelial differentiation
genes including s100c and p21/waf that are co-induced in
neurons by axotomy where it is thought to stimulate the
extension of axons via regulation of actin-based motility
in growth cone ruffles.43 Although SPRR1A is not
detected in naı̈ve DRGs or peripheral nerves, it is
intensely detected in DRGs and nerves following periph-
eral sciatic nerve injury.44 It is only minimally detected
following injury of centrally projecting branches of
DRG neurons.
Galanin is a neuropeptide with widespread distribu-
tion in the central and peripheral nervous system.45
Although treatment with exogenous galanin promotes
nerve regeneration,45,46 it demonstrates both facilitatory
and inhibitory effects on nociception, depending on pain
model persistence, dose, and mode of delivery.47
In addition to the Rap1 signaling pathway (part of
the RAS superfamily), many other interesting gene clus-
ters were significantly enriched for KEGG pathways and
differentially regulated at three days post-nerve injury in
this study. Aldosterone injection (i.pl. or i.t), for exam-
ple, induces rapid kinase signaling cascades in the cyto-
plasm, including activation of another RAS signaling
pathway pain signaling responder, extracellular
stimulus-regulated kinase 1/2 (ERK1/2), increasing acti-
vation of DRGs in vitro and mechanical allodynia
in vivo.29,48
The neuroactivator, glutamate synapse, and long-
term potentiation clusters were upregulated though not
unexpectedly during persistent pain, as they underlie
short- and long-term synapse formation and neurogen-
esis.49 The upregulated retrograde endocannabinoid
signaling cluster would be a factor in endogenous
pain control.
21 Days post-TIC injury. Despite the finding that transcrip-
tion levels of most genes significantly upregulated at
three days are returned to constitutive levels by 21
days post-TIC nerve injury (25 of 32 genes), the three
Danaher et al. 15
RAGs, Sprr1a, Atf3, and Gal, remained
upregulated> 15-, 2.7-, and 2.4-fold three weeks later.
The continued over-expression of RAGs is consistent
with the concept that these epigenetic mechanisms play
an important role in the persistence of trigeminal injury-
induced nerve regeneration and allodynia.44,50 Likewise,
this suggests the neuroplasticity in peripheral nerves is
continuing though perhaps not in an adaptive manner
since hypersensitivity in this model persists for at least
six months.14,15
The notable increase in expression of insulin signaling
pathway and resistance clusters at 21 days post-nerve
injury may reflect the requirement for insulin in axon
extension, viability, and repair.51,52 Insulin signaling in
neuronal DRG perikarya has been shown to upregulate
insulin receptor, drive distal sensory axon regrowth,
rescue retrograde alterations of axons, and alter axon
calcitonin gene-related peptide expression in regenerat-
ing sprouts.51 At day 21 post-nerve injury, insulin sig-
naling pathway and resistance expression clusters are
also reflective of the trophic satellite glial cell support
for the ongoing neuronal repair. Listed with the gastric
acid secretion cluster is phosphoinositide-specific-
phospholipase Cb, which is the main effector of Gaq
stimulation coupling numerous pain-related neurotrans-
mitter receptors and hormones to post-transcriptional
gene regulation.53
Molecules encoded by genes dysregulated 21 days
post-TIC nerve injury have a variety of molecular func-
tions including those involved in binding metal ion (e.g.
Cacna2d1 and Kcnc2), proteins (SUMO transferase,
serine-type endopeptidase), laminin-1, GTP, sequence-
specific DNA (H3K9, RNA polymerase II regulatory
region sequence-specific, and transcription factor activi-
ty), and nucleic acids. Nuclei acids released during
mechanical nerve trauma are highly pro-inflammatory
resulting in further tissue damage due to their excessive
stimulation of the immune response. Endogenous bind-
ing of released nucleic acid would enhance reparative
processes in the local environment.
Global acetylation of H3K9 decreased in the
ipsilateral trigeminal ganglia at 3 weeks
The H3K9ac protein was expressed in the nuclei of neu-
rons and the majority of non-neuronal profiles. Only a
minority of the GS-labeled satellite glial cells in the TG
demonstrated co-labeling with H3K9 acetylation protein
after TIC nerve injury. Further investigation is needed to
explore the non-neuronal cells in the TG expressing
H3K9ac and the impact of orofacial neuropathic pain
on other glia and endothelial cells in the TG and brain-
stem (such as Schwann cells, oligodendrocytes, astro-
cytes, and ependymal cells) to fully understand the
epigenetic mechanisms involved in the persistence of
nociceptive pathway activation leading to chronic pain.
The global HDAC immunohistochemistry decrease at
day 21, though not much affected at day 3, provides
support that epigenetic modulation through histone
deacetylation contributes to the maintenance of pain
after tissue healing.
Diminished hypersensitivity after preemptive
treatment with HDACi’s
As it is reported that HDACi needs to be administered
five days prior to the nerve injury surgery to have an
analgesic effect,5 this same treatment regimen was fol-
lowed in the present study. The HDACi’s SAHA and
MS-275 used preemptively in this study had the ability
to prevent the development of persistent orofacial neu-
ropathic pain. Hypersensitivity reversed to baseline three
weeks after TIC in mice receiving HDACi’s preemptive-
ly. The three-week time point ostensibly coincides with
the completion of tissue repair from the TIC nerve injury
surgery. This further supports a role for HDAC deace-
tylation following TIC injury and is an indicator that
epigenetic modulation is a major contributor to persist-
ing neuropathic pain.
Khangura et al. have reviewed numerous studies iden-
tifying the potential of HDACi’s to restore nociceptive
thresholds by increasing histone acetylation, while other
studies reported that histone acetylation promotes
pain.54 Evidence was provided for both nerve injury
and inflammatory pain models, primarily examining sci-
atic nerve and spinal cord plasticity. It has been shown
that neuron-restrictive silencer factor expression upregu-
lated in DRG neurons after peripheral nerve injury is
mediated through epigenetic mechanisms causing C-
fiber dysfunction and promoting neuropathic pain.55-57
HDACi’s have been shown to relieve acute formalin
pain-related behaviors by upregulating mGlu2 receptor
gene in DRG.3 In a previous study by others, preemptive
SAHA was also effective in reducing peripheral nerve
mechanical and thermal hypersensitivity induced by
skin incision along with enhanced spinal cord CXCL1
(KC) and CXCR2 (MIP-2) mRNA expression.57
Relationship of gene expression to the chronicity
of pain
The RT-PCR authenticated the relevance of the three
most overexpressed RAG gene transcripts at both 3
and 28 days post-TIC injury. The RT-PCR indicates
these genes (Sprr1a, Gal, and Atf3) play a role among
perhaps many others in the nerve reparative processes
vital to restoration of nociception and diminished pain
as indicated by others for DRG.41,42,52,58 Although the
Gal and Atf3 were diminished to control levels by 28
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days, the Sprr1a remained elevated at that time point in
both the treated and untreated mice with nerve injury.
Our initial report describing the TIC model demonstrat-
ed ATF3 in the TG of mice with TIC nerve injury using
immunocytochemistry.14
The data suggest that the HDACi’s SAHA and MS-
275 could act as pre-surgical analgesics for the preven-
tion of orofacial neuropathic pain. In another study,
HDACi’s strongly increased GAD65 activity, restored
GABA synaptic function, and relieved sensitized pain
behavior.57 The downregulation of post-synaptic genes,
such as vesicular GABA transporter VGAT and Gad2 in
the GABA inhibitory neurons of the trigeminal spinal
subnucleus caudalis (SpVc) or spinal cord following
nerve injury, leads to neuropathic pain.59,60 Epigenetic
silencing of Kþ channels has previously been demon-
strated following spinal nerve ligation.2 In that study,
acetylation was decreased and methylation was
increased in the DRG on histone 3 of the promoter
regions for the K1 channel. These investigators were
able to restore expression of 40 of 42 silenced K1
channel-associated genes following inhibition of G9a,
another methyltransferase that acts on lysine residues
in histone 3.2
Limitations of the study
The aim of this study was to identify evidence of epige-
netic changes associated with the TIC nerve injury model
as demonstrated by three independent experimental out-
puts: (1) altered H3K9 acetylation, (2) altered gene
expression patterns, and (3) effects of chronic histone
deacetylase inhibition. The study is not without limita-
tions. Regarding gene expression profiling, a major lim-
itation is that gene expression profiling has not yet been
done to determine the effect of the HDACi’s on the
transcriptional expression changes associated with the
TIC injury over a rigorous time course. Understanding
the epigenetic mechanisms remains key to a better
understanding of the establishment of chronic pain. In
regard to RAG gene expression, it is not yet known
whether the three differentially expressed RAG genes
selected for RT-PCR authentication (potentially impor-
tant in nerve repair) are affected by HDACi’s or whether
other genes are the temporally regulated targets of
HDACi’s. Future follow-on studies are needed that
would benefit from the inclusion of both sham and
naı̈ve controls, additional time points, other tissues,
investigation of other epigenetic regulatory pathways,
and the inflammatory response component.
Summary
Evidence is accumulating that chromatin-modifying
enzymes and associated mechanisms that alter
chromatin in response to pathological pain signaling
are playing a role in the transition from acute to persis-
tent pain. Increased expression of nerve RAGs at both
days 3 and 21 provides support for their relevance after
persisting trigeminal nerve injury, as shown with other
peripheral nerve injuries. Several ion channels-associated
genes (Cacna2d1 and Kcnc2) and inflammatory media-
tor genes (Cd68, Ccl2, Cxcl10, and Cxcl13) had
increased expression after trigeminal nerve injury,
while increases in the inflammatory mediator genes
CD177, Igkv14–126, IgLy6a, Ly6a, and Ighg have not
been reported previously. The present study provides
additional clear immunophenotypic evidence for global
decreased acetylated histone H3K9 in the trigeminal
ganglia, evidence of altered gene expression by microar-
ray, the ability of HDACi’s (MS275, SAHA) to attenu-
ate mechanical hypersensitivity, and the gene expression
increases of nerve RAGs (Sprr1a, Gal, and Atf3) during
the first three weeks after induction of orofacial neuro-
pathic pain using our trigeminal inflammatory constric-
tion nerve injury mouse model. Studying further, the
molecular effects of HDACi’s and their ability to
arrest the transition to chronic hypersensitivity will
lead to valuable insight into understanding the clinical
capabilities of HDACi’s as beneficial therapy for orofa-
cial neuropathic pain.
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